Phathom Pharmaceuticals (PHAT) Income towards Parent Company (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Income towards Parent Company for 9 consecutive years, with -$28.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Income towards Parent Company rose 66.44% year-over-year to -$28.0 million; the TTM figure through Jun 2026 stood at -$152.3 million (up 51.82% YoY), while the FY2025 annual figure was -$458.6 million, up 11.41% from the prior year.
• Income towards Parent Company advanced to -$28.0 million in Q2 2026 per PHAT's latest filing, from -$48.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$19.8 million in Q4 2024 and bottomed at -$118.7 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$58.7 million across 5 years, with a median of -$49.4 million in 2022.
• On a YoY basis, Income towards Parent Company climbed as much as 79.37% in 2024 and fell as far as 175.73% in 2024.
• Phathom Pharmaceuticals' Income towards Parent Company stood at -$47.4 million in 2022, then tumbled by 102.1% to -$95.9 million in 2023, then soared by 79.37% to -$19.8 million in 2024, then fell by 6.87% to -$21.1 million in 2025, then tumbled by 32.41% to -$28.0 million in 2026.
• Business Quant data shows PHAT's Income towards Parent Company at -$28.0 million in Q2 2026, -$48.0 million in Q1 2026, and -$21.1 million in Q4 2025.